Key opinion leader Alicia Morgans, MD, MPH, considers the role of lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer management.
Radical Prostatectomy Shows Less Genitourinary Toxicity in Localized Prostate Cancer
April 30th 2025A study of 47,387 patients found radical prostatectomy had the lowest long-term risk of severe genitourinary complications after localized prostate cancer treatment compared to combination therapies.
Read More
Testosterone Recovery After Prostate Cancer Treatment Suspension: EMBARK Analysis
April 29th 2025The EMBARK analysis showed most men regained testosterone after stopping enzalutamide/leuprolide or placebo/leuprolide for prostate cancer with good PSA response, and recovery was common across age groups.
Read More